ABcann Medicinals Set to Launch IPO This Week on TSXV

According to efficient markets theory, the chances of finding hundred-dollar bills lying on the ground are slim, at best. When one is dropped, some well-informed investor is quick to pick it up. However, with Abcann Medicinals set to launch its initial public offering (IPO) on the TSX Venture Exchange on May 4, the chances of finding those elusive hundreds have increased significantly. Investors will have an opportunity to take up shares in one of Canada’s major legal cannabis producers. With the marijuana recreational market in Canada set for legalization, the Abcann Medicinals IPO will level the playing field and offer to the public a chance to multiply their dollars into hundreds.

Abcann Medicinals, which will trade under the symbol ABCN, may be new to the public markets, but the company is a veteran in the industry. It was founded in 2014 by Ken Clement, who observed the lack of quality and consistency in the medical marijuana available and the resulting variability in dosages that posed risks to achieving effective therapeutic regimens. He vowed to “to deliver consistent, standardized medicinal cannabis that the public and patients can consistently rely on.”